Biotech IV Monitor

REGN — Regeneron Pharmaceuticals Inc.

$84.0B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Regeneron Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts52 Phase 3
Market cap$84.0B
Cash & investments$18.68Bas of Sep 30, 2026
Recent 8-K filings1latest 2026-10-30

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 Dupilumab
Atopic Dermatitis · NCT02612454
October 2026
Primary data collected
Phase 3 Ravulizumab
Paroxysmal Nocturnal Hemoglobinuria · NCT05133531
September 2026
Primary data collected
Phase 3 mibavademab
Generalized Lipodystrophy · NCT06548100
July 2026
Primary data collected
Phase 2 Odronextamab
B-cell Non-Hodgkin Lymphoma (B-NHL) · NCT03888105
June 2026
Primary data collected
Phase 2 Trevogrumab-Part A
Obesity · NCT06299098
June 2026
Primary data collected

Upcoming readouts

Phase 2 REGN7999
Non-Transfusion Dependent Beta-Thalassemia (NTDT) · NCT06421636
December 2026
Ongoing
Phase 2 Alirocumab
Hypercholesterolemia · NCT07477704
December 2026
Ongoing
Phase 3 Fianlimab
Melanoma · NCT05608291
January 2027
Ongoing
Phase 2 REGN7508
Atrial Fibrillation (AF) · NCT07175428
February 2027
Recruiting
Phase 3 REGN7508
Venous Thromboembolism (VTE) · NCT07015905
February 2027
Recruiting

Target dates already passed

These dates have elapsed; the company may have reported, or guidance may have shifted.

Phase 2 cemiplimab
Melanoma · NCT06190951
November 2026
Ongoing
Phase 2 Olatorepatide
Overweight or Obesity · NCT07431086
November 2026
Ongoing
Phase 1/2 REGN7075
Advanced Solid Tumors · NCT04626635
November 2026
Ongoing

Cash position

Regeneron Pharmaceuticals Inc. reported $18.68B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-10-30). It reported net income of $1.95B for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-10-30

Companies working on similar indications

Discussion

No messages yet. If you follow REGN, you can start the conversation.
Track REGN in real time
See live implied volatility for REGN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on REGN
Contact — questions or corrections about REGN: dukeupt@gmail.com